Patient care, the patient’s way: an evaluation of method of levels therapy

ISRCTN ISRCTN14514953
DOI https://doi.org/10.1186/ISRCTN14514953
ClinicalTrials.gov (NCT) Nil known
Clinical Trials Information System (CTIS) Nil known
Integrated Research Application System (IRAS) 266408
Protocol serial number 2 6 6408, IRAS 266408
Sponsor University of East London
Funder Investigator initiated and funded
Submission date
30/01/2020
Registration date
11/02/2020
Last edited
16/12/2024
Recruitment status
No longer recruiting
Overall study status
Ongoing
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Psychological health services in the UK are predominantly expert-led and diagnosis driven. Based on clinical recommendations, a widely used psychological therapy that is heavily disorder-focused (i.e., diagnosis-led) is Cognitive Behaviour Therapy (CBT). There are different models of CBT based on different disorders (e.g., CBT for depression, CBT for panic etc.). In reality, patients often have multiple diagnoses and thus utilising a transdiagnostic-orientated approach (i.e., one that is not focused on specific disorders/diagnoses) might be a more helpful alternative.
Method of Levels (MOL) is an innovative transdiagnostic cognitive therapy based entirely on levels of psychological distress as judged by the patient rather than on diagnoses, symptoms or observable behaviour. MOL is based on Perceptual Control Theory (PCT: Powers, 2005), a theory not attached to notions of normality or abnormality – the main tenet is ‘behaviour is the control of perception’, hence symptom classification is meaningless as each individual will be controlling for different goal states.
MOL aims to be patient-led (patient-perspective care) by allowing the patient to take more control over how therapy is accessed and used. MOL involves the patient being assessed for psychological distress (i.e., how bothered the patient is by their distress). This acknowledges distress as a changing process and hence is less stigmatising. As therapy is not diagnosis-led, multiple diagnoses are not an issue. Session length is dictated by the patient who does not need to name the problem. Patients self-identify change as they decide when to stop attending. Within this model, it is acknowledged that change is idiosyncratic and therefore therapy should be offered accordingly – patient-led rather than service-led.
The overarching goal of the study is to demonstrate potential improvements to psychological services (more efficient use of resources/lower rates of non-attendance/better outcomes) and to maximise patient participation in terms of nature and frequency of care, ultimately to move towards providing a service that is more patient-orientated and-led.

Who can participate?
Patients aged 18 – 65 years who meet eligibility to receive psychological input from the Psychological Therapies Service in Waltham Forest, London (North East London NHS Foundation Trust) can take part (updated 10/03/2020). The majority of difficulties within the service fall under anxiety, depression or interpersonal issues.

What does the study involve?
The current study will implement and evaluate a MOL intervention within an NHS secondary care psychological service, with patients who have longstanding and multiple psychological difficulties. Questionnaire data will be collected from participants for three weeks prior to starting therapy, during therapy (maximum 9 months) and at 1 and 3 month follow-up. The questionnaires will focus on the psychological difficulties the participant is bothered by and how these are experienced and managed. The questionnaire data will be used to monitor changes throughout the study. In addition to these questionnaires, participants will also be invited to take part in an individual interview to explore their experiences of MOL and the patient-led booking system. Both questionnaire and interview data will be analysed separately to determine how well MOL works in this type of setting.

What are the possible benefits and risks of participating?
Participants who take part in the study will receive psychological input much sooner than if they remain on the psychological waiting list.
Receiving psychological therapy can make participants more aware of difficult emotions and/or experiences; MOL is not expected to cause greater distress than other psychological therapies routinely offered by the service. Participants are free to withdraw at any point and/or opt for routine psychological therapy. Contact numbers of supporting agencies will be provided to seek immediate support outside of the study.

Where is the study run from?
Psychological Therapies Service (Waltham Forest) (UK)

When is the study starting and how long is it expected to run for?
February 2020 to April 2026

Who is funding the study?
Investigator-initiated and funded

Who is the main contact?
Dr Trishna Patel
t.patel@uel.ac.uk
Dr Kavus Davis
Kavus.Davis@nelft.nhs.uk

Contact information

Dr Trishna Patel
Scientific

University of East London
School of Psychology
Stratford Campus
London
E15 4LZ
United Kingdom

ORCiD logoORCID ID 0000-0002-7995-7328
Phone +44 (0)20 8223 6392
Email t.patel@uel.ac.uk

Study information

Primary study designInterventional
Study designSingle centre interventional open clinical trial
Secondary study designOpen clinical trial (studying a novel intervention)
Study type Participant information sheet
Scientific titlePatient care, the patient’s way: an evaluation of method of levels therapy in secondary care
Study objectivesObjective 1 -
1: Are scores on symptom measures, psychological distress and goal conflict reorganisation statistically different pre and post therapy?
2: If yes, what are the treatment effect sizes?

Objective 2 -
1: What are patients’ experiences of a) MOL and b) the patient-led booking system?
2: What changes need to be implemented?

Objective 3 -
1: What is the average number of sessions a) attended, b) not-attended and c) cancelled?
2: What is the average a) time interval between appointments and b) length of therapy sessions?
3: What is the difference between patients’ expectation of the number of sessions required and the number attended?
4: What is the treatment efficiency?
Ethics approval(s)Approved 29/11/2019, London - Queen Square Research Ethics Committee (REC) (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH; +44 (0)207 104 8061; NRESCommittee.London-QueenSquare@nhs.net) ref: 19/LO/1681
Health condition(s) or problem(s) studiedMental health
InterventionIntervention - Method of Levels (MOL) therapy
Delivery - Face-to-face by a clinical psychologist
Who will be offered the intervention - All participants referred for Psychology eligible to take part will be offered the intervention.

MOL is an innovative transdiagnostic cognitive therapy based entirely on levels of psychological distress as judged by the patient rather than on diagnoses, symptoms or observable behaviour. MOL aims to be patient-led (patient-perspective care) by allowing the patient to take more control over how therapy is accessed and used.

Duration -
Baseline: 3 weeks
Intervention: maximum 9 months
Interviews and follow-up: maximum 3 months
Total possible time in study: 13 months
Intervention typeBehavioural
Primary outcome measure(s)

During the 3 week baseline, intervention phase (at the end of each therapy session) and at 1 and 3 month follow-up.
1. Clinical Outcomes in Routine Evaluation-outcome measure (CORE-OM)
2. Patient Health Questionnaire (PHQ-9)
3. Generalised Anxiety Disorder assessment (GAD-7)
4. Psychological distress measured by the Outcome Rating Scale (ORS)
5. Reorganisation of Conflict (RoC) subscale

Key secondary outcome measure(s)

Patient experience of the service measured using individual semi-structured interviews. These will take place following the intervention phase. Only one meeting will be offered (40-60 minutes). Either face-to-face at the service or via telephone/Skype.

Completion date01/04/2026

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit65 Years
SexAll
Target sample size at registration30
Key inclusion criteriaCurrent inclusion criteria as of 10/03/2020:
1. Patients who meet eligibility to receive psychological input from the Psychological Therapies Service in Waltham Forest, London (North East London NHS Foundation Trust) will meet inclusion criteria for the study. Referrals for psychosis, memory problems or addiction/substance misuse are directed to other services, the majority of difficulties within the service fall under anxiety, depression or interpersonal issues
2. Aged between 18 and 65
3. Able to consent to take part
4. Able to understand written information provided
5. Able to engage in therapy without an interpreter

_____
Previous inclusion criteria:
1. Patients who meet eligibility to receive psychological input from the service will meet inclusion criteria for the study. Referrals for psychosis, memory problems or addiction/substance misuse are directed to other services, the majority of difficulties within the service fall under anxiety, depression or interpersonal issues
2. Aged between 18 and 65
3. Able to consent to take part
4. Able to understand written information provided
5. Able to engage in therapy without an interpreter
Key exclusion criteriaPatients will not be eligible to take part if they require an interpreter or written material to be translated from English
Date of first enrolment01/12/2022
Date of final enrolment01/06/2024

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Psychological Therapies Service (Waltham Forest)
26 Low Hall Lane
Walthamstow
London
E17 8BE
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
IPD sharing planThe datasets generated and/or analysed during the current study are not expected to be made available due to anonymity and confidentiality reasons.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

16/12/2024: The intention to publish date was changed from 30/12/2024 to 30/12/2026.
03/09/2024: The overall end date was changed from 01/01/2025 to 01/04/2026.
18/09/2023: The overall end date was changed from 01/06/2024 to 01/01/2025.
27/10/2022: The following changes were made to the trial record:
1. The recruitment start date was changed from 24/02/2020 to 01/12/2022.
2. The recruitment end date was changed from 07/05/2021 to 01/06/2024.
3. The overall end date was changed from 07/05/2021 to 01/06/2024.
4. The intention to publish date was changed from 30/12/2021 to 30/12/2024.
5. The plain English summary was updated to reflect these changes.
23/03/2020: Internal review.
20/03/2020: Due to current public health guidance, recruitment for this study has been paused.
10/03/2020: The following changes were made to the trial record:
1. The inclusion criteria were changed.
2. The plain English summary was updated to reflect these changes.
25/02/2020: Internal review.
24/02/2020: Internal review.
03/02/2020: Trial’s existence confirmed by London - Queen Square Research Ethics Committee